NDAORALCAPSULE
Approved
Jul 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
EMTRIVA (emtricitabine) by Gilead Sciences is nucleoside reverse transcriptase inhibitors [moa]. Approved for hiv infection, hiv-2 infection, pre-exposure prophylaxis of hiv infection. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMTRIVA is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved in 2003 for HIV-1, HIV-2, hepatitis B infection, and HIV pre-exposure prophylaxis. It works by inhibiting reverse transcriptase, blocking viral replication in HIV-infected cells. The drug is a foundational component of modern antiretroviral regimens.
$0.312MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D utilization signals team focus on generic transition planning and lifecycle extension strategies.
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Indications (3)
Worked on EMTRIVA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.